Berkshire Hathaway Inc Class B vs BIO-TECHNE Corp — how do they compare? Berkshire Hathaway Inc Class B trades at $491.97, while BIO-TECHNE Corp trades at $71.23 (market cap $11.12B). The key difference: BIO-TECHNE Corp pays a 0.45% dividend while Berkshire Hathaway Inc Class B pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, Berkshire Hathaway Inc Class B nearer its low. Which is the better fit depends on your goals.
| BRK.B | TECH | |
|---|---|---|
Sector | Financials | Health |
52-Week High | $513.70 | $71.38 |
52-Week Low | $459.10 | $43.31 |
Market Cap | — | $11.12B |
Enterprise Value | — | $11.20B |
Dividend Yield | — | 0.45% |
Signals from Pluang's Aura AI — not financial advice
BRK.B trades at $496.79, up 0.63% today, with technical indicators showing a bullish trend from moving averages while oscillators remain neutral. The stock is supported by strong analyst consensus with 57% buy ratings and no sell recommendations. Recent earnings reports highlight Berkshire Hathaway's diversified portfolio strength and consistent cash flow generation.
The outlook remains positive given institutional confidence and technical support near $494, though investors face risks from macroeconomic sensitivity and regulatory scrutiny. Upside potential exists if the company maintains its earnings momentum and capital allocation strategy.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Berkshire Hathaway is a holding company with diverse subsidiaries, primarily in insurance through Geico and its reinsurance groups. It reinvests profits into various industries, owning Burlington Northern Santa Fe (railroad), Berkshire Hathaway Energy, and major manufacturing, service, and retail businesses like Precision Castparts and Lubrizol. The company operates in a highly decentralized manner.
Read more on BRK.B →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →